Evidence map›Paper›PMID 32978434›Full record

ArticleScientific reports2020

Rab13 regulates sEV secretion in mutant KRAS colorectal cancer cells.

Scott A Hinger, Jessica J Abner, Jeffrey L Franklin, Dennis K Jeppesen, Robert J Coffey, James G Patton

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Function and regulation of Rab GTPases in cancers.Cell biology and toxicology · 2024
    Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Scott A HingerDepartment of Biological Sciences, Vanderbilt University Medical Center, Nashville, TN, 37235, USA.
Jessica J AbnerDepartment of Biological Sciences, Vanderbilt University Medical Center, Nashville, TN, 37235, USA.
Jeffrey L FranklinDepartment of Cell and Developmental Biology, Vanderbilt University Medical Center, Nashville, TN, 37235, USA.ORCID http://orcid.org/0000-0002-7111-4449
Dennis K JeppesenDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, 37235, USA.ORCID http://orcid.org/0000-0002-7480-8083
Robert J CoffeyDepartment of Cell and Developmental Biology, Vanderbilt University Medical Center, Nashville, TN, 37235, USA.ORCID http://orcid.org/0000-0002-2180-3844
James G PattonDepartment of Biological Sciences, Vanderbilt University Medical Center, Nashville, TN, 37235, USA. james.g.patton@vanderbilt.edu.
Vanderbilt University Medical Center · USThe Ohio State University · USVanderbilt University · US

Funding

Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9M
Vanderbilt-Ingram Cancer Center SPORE in Gastrointestinal CancerP50CA236733 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI STEPHEN W. FESIK · 2019 to 2026
$19.6M
Roles for Supermeres in CRC ProgressionP01CA229123 · NCI · VANDERBILT UNIVERSITY · PI Alissa M Weaver · 2020 to 2026
$12.9M
Integrated approach to study early and late events in colonic neoplasia: mouse to manR35CA197570 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Robert J. Coffey · 2017 to 2026
$9.4M
Trafficking of eRNAs in K-Ras Mutant Colon CancerU19CA179514 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI COFFEY, ROBERT J. · 2013 to 2017
$5.3M
NCI NIH HHS CA179514NCI NIH HHS P01 CA229123NCI NIH HHS P50 CA236733NCI NIH HHS R35 CA197570NCI NIH HHS U19 CA179514NIDDK NIH HHS P30 DK058404
6 · The paper itself

Abstract

Small extracellular vesicles (sEVs), 50-150 nm in diameter, have been proposed to mediate cell-cell communication with important implications in tumor microenvironment interactions, tumor growth, and metastasis. We previously showed that mutant KRAS colorectal cancer (CRC) cells release sEVs containing Rab13 protein and mRNA. Previous work had shown that disruption of intracellular Rab13 trafficking inhibits epithelial cell proliferation and invasiveness. Here, we show that Rab13 additionally regulates the secretion of sEVs corresponding to both traditional exosomes and a novel subset of vesicles containing both β1-integrin and Rab13. We find that exposure of recipient cells to sEVs from KRAS mutant donor cells increases proliferation and tumorigenesis and that knockdown of Rab13 blocks these effects. Thus, Rab13 serves as both a cargo protein and as a regulator of sEV secretion. Our data support a model whereby Rab13 can mediate its effects on cell proliferation and invasiveness via autocrine and paracrine signaling.

Indexed as

MutationCell CommunicationCell MovementCell ProliferationColorectal NeoplasmsExosomesExtracellular VesiclesHumansIntegrin beta1Proto-Oncogene Proteins p21(ras)rab GTP-Binding ProteinsTumor Cells, CulturedTumor MicroenvironmentIntegrin beta1KRAS protein, humanProto-Oncogene Proteins p21(ras)RAB13 protein, humanrab GTP-Binding Proteins

Identifiers

PMID32978434
PMCPMC7519665
OpenAlexW3088550328

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.